Home › Compare › IGMS vs FCPT

IGMS vs FCPT: Dividend Comparison 2026

IGMS yields 157.48% · FCPT yields 6.05%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IGMS wins by $32.03M in total portfolio value
10 years
IGMS
IGMS
● Live price
157.48%
Share price
$1.27
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.08M
Annual income
$14,264,590.95
Full IGMS calculator →
FCPT
FCPT
● Live price
6.05%
Share price
$23.65
Annual div
$1.43
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.1K
Annual income
$5,775.28
Full FCPT calculator →

Portfolio growth — IGMS vs FCPT

📍 IGMS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIGMSFCPT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IGMS + FCPT cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
IGMS pays
FCPT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IGMS
Annual income on $10K today (after 15% tax)
$13,385.83/yr
After 10yr DRIP, annual income (after tax)
$12,124,902.31/yr
FCPT
Annual income on $10K today (after 15% tax)
$514.49/yr
After 10yr DRIP, annual income (after tax)
$4,908.99/yr
At 15% tax rate, IGMS beats the other by $12,119,993.32/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IGMS + FCPT for your $10,000?

IGMS: 50%FCPT: 50%
100% FCPT50/50100% IGMS
Portfolio after 10yr
$16.07M
Annual income
$7,135,183.12/yr
Blended yield
44.41%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on IGMS right now

IGMS
Analyst Ratings
8
Buy
10
Hold
Consensus: Hold
Price Target
$16.79
+1222.0% upside vs current
Range: $1.50 — $31.00
Altman Z
-3.8
Piotroski
3/9
FCPT
Analyst Ratings
5
Buy
10
Hold
Consensus: Hold
Price Target
$27.00
+14.2% upside vs current
Range: $25.00 — $29.00
Altman Z
1.4
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IGMS buys
0
FCPT buys
0
No recent congressional trades found for IGMS or FCPT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIGMSFCPT
Forward yield157.48% ✓6.05%
Annual dividend / share$2.00 ✓$1.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$32.08M$49.1K ✓
Annual income after 10y$14,264,590.95 ✓$5,775.28
Total dividends collected$29.79M ✓$24.1K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldHold
Analyst price target$16.79$27.00 ✓

Year-by-year: IGMS vs FCPT ($10,000, DRIP)

YearIGMS PortfolioIGMS Income/yrFCPT PortfolioFCPT Income/yrGap
1← crossover$26,448$15,748.03$11,401$700.92+$15.0K → IGMS
2$67,225$38,925.65$13,064$864.84+$54.2K → IGMS
3$164,398$92,467.65$15,051$1,072.48+$149.3K → IGMS
4$387,242$211,335.59$17,442$1,337.22+$369.8K → IGMS
5$879,585$465,236.23$20,340$1,677.08+$859.2K → IGMS
6$1,928,765$987,609.46$23,880$2,116.57+$1.90M → IGMS
7$4,087,744$2,023,965.18$28,241$2,689.36+$4.06M → IGMS
8$8,382,771$4,008,884.54$33,660$3,442.07+$8.35M → IGMS
9$16,652,792$7,683,226.74$40,456$4,439.95+$16.61M → IGMS
10$32,083,078$14,264,590.95$49,063$5,775.28+$32.03M → IGMS

IGMS vs FCPT: Complete Analysis 2026

IGMS — Stock

IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Full IGMS Calculator →

FCPT — REIT

FCPT, headquartered in Mill Valley, CA, is a real estate investment trust primarily engaged in the acquisition and leasing of restaurant properties. The Company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries.

Full FCPT Calculator →
📬

Get this IGMS vs FCPT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IGMS vs SCHDIGMS vs JEPIIGMS vs OIGMS vs KOIGMS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.